Breakthrough Infections: A Challenge towards Measles Elimination?
breakthrough infection
measles
measles vaccine
vaccination failures
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
04 Aug 2022
04 Aug 2022
Historique:
received:
15
07
2022
revised:
29
07
2022
accepted:
02
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Measles is one of the most contagious diseases known to man. Despite the existence of a safe and effective live attenuated vaccine, measles can appear in vaccinated individuals. Paradoxically, breakthrough cases increase as vaccination coverage in the general population rises. In measles endemic areas, breakthrough cases represent less than 10% of total infections, while in areas with high vaccination coverage these are over 10% of the total. Two different vaccination failures have been described: primary vaccination failure, which consists in the complete absence of humoral response and occurs in around 5% of vaccinated individuals; and secondary vaccination failure is due to waning immunity or incomplete immunity and occurs in 2-10% of vaccinees. Vaccination failures are generally associated with lower viral loads and milder disease (modified measles) since vaccination limits the risk of complicated disease. Vaccination failure seems to occur between six and twenty-six years after the last vaccine dose administration. This review summarizes the literature about clinical, serological, epidemiological, and molecular characteristics of measles breakthrough cases and their contribution to virus transmission. In view of the measles elimination goal, the assessment of the potential decline in antibody protection and the targeted implementation of catch-up vaccination are essential.
Identifiants
pubmed: 36013985
pii: microorganisms10081567
doi: 10.3390/microorganisms10081567
pmc: PMC9413104
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Am J Public Health. 2000 Oct;90(10):1515-20
pubmed: 11029980
Eur J Epidemiol. 2019 Oct;34(10):897-915
pubmed: 31624970
J Clin Microbiol. 1991 Jun;29(6):1148-50
pubmed: 1864932
Nat Rev Microbiol. 2006 Dec;4(12):900-8
pubmed: 17088933
Vaccines (Basel). 2019 Nov 28;7(4):
pubmed: 31795157
Lancet. 2017 Dec 2;390(10111):2490-2502
pubmed: 28673424
Hum Vaccin Immunother. 2016 May 3;12(5):1102-16
pubmed: 26631840
Lancet Microbe. 2022 Jan;3(1):e9
pubmed: 35544120
mBio. 2014 Apr 15;5(2):e01047
pubmed: 24736226
Euro Surveill. 2009 Dec 17;14(50):
pubmed: 20070934
Vaccine. 2008 Apr 16;26(17):2111-8
pubmed: 18343536
Clin Diagn Lab Immunol. 2004 Jan;11(1):119-22
pubmed: 14715557
J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
PLoS One. 2013 Sep 20;8(9):e73374
pubmed: 24073194
Euro Surveill. 2019 Jan;24(3):
pubmed: 30670145
Enferm Infecc Microbiol Clin. 2017 Nov;35(9):569-573
pubmed: 27262819
Euro Surveill. 2019 Apr;24(17):
pubmed: 31039835
Front Microbiol. 2011 Dec 16;2:247
pubmed: 22319511
Int J Mol Sci. 2020 Jun 22;21(12):
pubmed: 32580384
JAMA. 1990 May 9;263(18):2467-71
pubmed: 2278542
Clin Diagn Lab Immunol. 2003 May;10(3):411-6
pubmed: 12738640
J Gen Virol. 2019 Dec;100(12):1593-1594
pubmed: 31609197
J Med Virol. 1998 Dec;56(4):337-41
pubmed: 9829639
J Infect Dis. 2011 Jul;204 Suppl 1:S559-63
pubmed: 21666213
Wkly Epidemiol Rec. ;92(9-10):97-105
pubmed: 28262010
Clin Infect Dis. 2018 Oct 15;67(9):1315-1319
pubmed: 29878209
J Pediatr. 1973 May;82(5):908-11
pubmed: 4698971
Epidemiol Infect. 2010 Jul;138(7):1012-5
pubmed: 19878613
J Infect Dis. 2011 Jul;204 Suppl 1:S549-58
pubmed: 21666212
Vaccine. 2021 Sep 7;39(38):5346-5350
pubmed: 34393016
Med Microbiol Immunol. 2016 Jun;205(3):201-8
pubmed: 26935826
Clin Vaccine Immunol. 2012 Nov;19(11):1810-7
pubmed: 22971778
J Pediatr. 1972 Aug;81(2):217-30
pubmed: 5042481
J Infect Dis. 2004 May 1;189 Suppl 1:S123-30
pubmed: 15106101
Clin Infect Dis. 2018 Oct 15;67(9):1320-1321
pubmed: 29878095
Infect Control Hosp Epidemiol. 2019 Dec;40(12):1407-1415
pubmed: 31587686
Vaccine. 2003 Nov 7;21(31):4597-603
pubmed: 14575773
J Gen Virol. 2001 Oct;82(Pt 10):2463-2474
pubmed: 11562539
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):832-3
pubmed: 26247437
Clin Infect Dis. 2014 May;58(9):1205-10
pubmed: 24585562
J Pediatr. 1977 Jan;90(1):1-12
pubmed: 12253
J Prim Health Care. 2013 Jun 01;5(2):92
pubmed: 23748388
Euro Surveill. 2014 Sep 04;19(35):
pubmed: 25210982
Elife. 2021 Jun 24;10:
pubmed: 34165077
Pediatrics. 2013 Nov;132(5):e1126-33
pubmed: 24144708
J Pediatr. 1973 May;82(5):802-8
pubmed: 4698954
Arch Pediatr Adolesc Med. 2007 Mar;161(3):294-301
pubmed: 17339511
Pediatr Infect Dis J. 1990 Feb;9(2):101-10
pubmed: 2179836
Epidemiol Infect. 2018 Oct;146(13):1707-1713
pubmed: 30081972
Hum Vaccin Immunother. 2016;12(1):239-43
pubmed: 26836329
Pediatr Infect Dis J. 2019 Sep;38(9):e230-e232
pubmed: 31261364
Viruses. 2022 May 17;14(5):
pubmed: 35632809
Euro Surveill. 2018 Aug;23(34):
pubmed: 30153884
Vaccine. 2000 Dec 8;19(9-10):1093-6
pubmed: 11137243
Commun Dis Intell Q Rep. 2009 Mar;33(1):21-6
pubmed: 19618764
Am J Public Health. 1989 Apr;79(4):475-8
pubmed: 2929807
Viruses. 2021 Oct 02;13(10):
pubmed: 34696412
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1495-1500
pubmed: 34710074
Infect Genet Evol. 2019 Nov;75:103943
pubmed: 31255832